Oncology · mTOR InhibitorRegulatory Approvalcommercialmid-term

Apotex submits ANDA for Everolimus, FDA review in progress

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 6:34:17 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of an ANDA for Everolimus by Apotex signals the potential entry of a generic competitor in the oncology market. This could disrupt pricing strategies and market share for current branded products, necessitating a reassessment of revenue forecasts. Regulatory context from FDA (FDA AP — EVEROLIMUS (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of a generic Everolimus on revenue forecasts and market positioning. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · mTOR Inhibitor, 6 regulatory and 4 competitive items passed relevance filtering for Apotex.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application. This submission may increase competition in the oncology market for Everolimus, potentially impacting pricing and market share for existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — EVEROLIMUS (ORIG) (FDA). Entity match (everolimus); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The FDA's review process for the ANDA will determine the timeline for market entry, which could influence compliance and labeling strategies for current products.

Key Risks

Elevated medium regulatory exposure for Apotex could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a generic Everolimus could lead to price erosion and loss of market share for existing brands, impacting overall revenue in the oncology segment.
Upside for Apotex may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Apotex may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact of a generic Everolimus on revenue forecasts and market positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's decision timeline and any subsequent market entry by Apotex.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — EVEROLIMUS (ORIG)
FDAhigh relevance
Entity match (everolimus); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — EVEROLIMUS (ORIG)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POSACONAZOLE (ORIG)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — IMIQUIMOD (SUPPL)
FDAhigh relevance
Entity match (apotex); Regulatory pathway relevance (nda)
FDA document
View source
MHRA safety review gives UK plasma donations go ahead
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA grants priority review for KEYTRUDA supplemental application
Humanexa Signalsmedium relevance
Moderate corpus alignment

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Centromere protein I promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR-CDK2 cascade.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Mapping family involvement in music therapy for children and adolescents with cancer: a scoping review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Apotex
Everolimus

Commercial impact

medium

The introduction of a generic Everolimus could lead to price erosion and loss of market share for existing brands, impacting overall revenue in the oncology segment.

Regulatory impact

medium

The FDA's review process for the ANDA will determine the timeline for market entry, which could influence compliance and labeling strategies for current products.

What to watch

Monitor the FDA's decision timeline and any subsequent market entry by Apotex.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.